Ignite Creation Date:
2024-05-06 @ 1:30 PM
Last Modification Date:
2024-10-26 @ 1:15 PM
Study NCT ID:
NCT04040725
Status:
WITHDRAWN
Last Update Posted:
2019-12-17
First Post:
2019-07-30
Brief Title:
Rogaratinib for BCG Refractory High Risk Non-Muscle Invasive Bladder Cancer With FGFR12 Overexpression
Sponsor:
Dana-Farber Cancer Institute
Organization:
Dana-Farber Cancer Institute
Key Dates - Follows AllAPIJSON File Order
Start Date:
2019-11-27
Start Date Type:
ACTUAL
Primary Completion Date:
2019-11-27
Primary Completion Date Type:
ACTUAL
Completion Date:
2019-11-27
Completion Date Type:
ACTUAL
First Submit Date:
2019-07-30
First Submit QC Date:
July 30 2019
Study First Post Date:
2019-08-01
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2019-12-13
Last Update Post Date:
2019-12-17
Last Update Post Date Type:
ACTUAL